BACKGROUND: 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme catalyzes interconversion of inactive cortisone to active cortisol. Its expression in adipose tissue has been associated with obesity and some of its metabolic disorders. Controversies regarding which fat depots [subcutaneous adipose tissue (SAT) or visceral adipose tissue (VAT)] have higher expression still remain. The aim of this work was to evaluate 11beta-HSD1 expression in SAT and VAT of obese patients and evaluate its association to metabolic features of metabolic syndrome. METHODS: In 32 morbidly obese patients, paired samples of SAT and VAT were collected. All patients, 40.2+/-12.3 years and 36.7+/-3.8 body mass index (BMI), underwent sleeve gastrectomy or laparoscopic gastric bypass. Gene expression of 11beta-HSD1 in adipose tissue samples were determined by real-time reverse transcriptase polymerase chain reaction. Spearman correlation test was used to evaluate relationships between 11beta-HSD1 levels and clinical and biochemical parameters. RESULTS: 11beta-HSD1 mRNA levels were higher in SAT than in VAT, with median expression levels of 11.4 arbitrary units (AU) and 7.8 AU, respectively (p=0.03). SAT 11beta-HSD1 mRNA were correlated with VAT mRNA levels (r=-0.6, p=0.018) and hip circumference (r=0.66, p=0.018). SAT 11beta-HSD1 levels increase parallel according to BMI category. We did not find a correlation between SAT or VAT with fasting glucose (r=0.15, p=NS), total cholesterol (r=0.13, p=NS), triglycerides (r=0.04, p=NS), and high-density lipoprotein (r=-0.16, p=NS). However, SAT expression in patients with features of MS was higher than those without features of MS. CONCLUSIONS: Our results demonstrate that SATs express higher 11beta-HSD1 mRNA levels than VAT. This finding highlights the importance of SAT in obesity and its possible role on metabolic disorders associated with obesity.
BACKGROUND:11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme catalyzes interconversion of inactive cortisone to active cortisol. Its expression in adipose tissue has been associated with obesity and some of its metabolic disorders. Controversies regarding which fat depots [subcutaneous adipose tissue (SAT) or visceral adipose tissue (VAT)] have higher expression still remain. The aim of this work was to evaluate 11beta-HSD1 expression in SAT and VAT of obesepatients and evaluate its association to metabolic features of metabolic syndrome. METHODS: In 32 morbidly obesepatients, paired samples of SAT and VAT were collected. All patients, 40.2+/-12.3 years and 36.7+/-3.8 body mass index (BMI), underwent sleeve gastrectomy or laparoscopic gastric bypass. Gene expression of 11beta-HSD1 in adipose tissue samples were determined by real-time reverse transcriptase polymerase chain reaction. Spearman correlation test was used to evaluate relationships between 11beta-HSD1 levels and clinical and biochemical parameters. RESULTS:11beta-HSD1 mRNA levels were higher in SAT than in VAT, with median expression levels of 11.4 arbitrary units (AU) and 7.8 AU, respectively (p=0.03). SAT 11beta-HSD1 mRNA were correlated with VAT mRNA levels (r=-0.6, p=0.018) and hip circumference (r=0.66, p=0.018). SAT 11beta-HSD1 levels increase parallel according to BMI category. We did not find a correlation between SAT or VAT with fasting glucose (r=0.15, p=NS), total cholesterol (r=0.13, p=NS), triglycerides (r=0.04, p=NS), and high-density lipoprotein (r=-0.16, p=NS). However, SAT expression in patients with features of MS was higher than those without features of MS. CONCLUSIONS: Our results demonstrate that SATs express higher 11beta-HSD1 mRNA levels than VAT. This finding highlights the importance of SAT in obesity and its possible role on metabolic disorders associated with obesity.
Authors: Nicholas M Morton; Janice M Paterson; Hiroaki Masuzaki; Megan C Holmes; Bart Staels; Catherine Fievet; Brian R Walker; Jeffrey S Flier; John J Mullins; Jonathan R Seckl Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Raoul Desbriere; Vincent Vuaroqueaux; Vincent Achard; Sandrine Boullu-Ciocca; Martin Labuhn; Anne Dutour; Michel Grino Journal: Obesity (Silver Spring) Date: 2006-05 Impact factor: 5.002
Authors: Z Krozowski; K X Li; K Koyama; R E Smith; V R Obeyesekere; A Stein-Oakley; H Sasano; C Coulter; T Cole; K E Sheppard Journal: J Steroid Biochem Mol Biol Date: 1999 Apr-Jun Impact factor: 4.292
Authors: L Alberti; A Girola; L Gilardini; A Conti; S Cattaldo; G Micheletto; C Invitti Journal: Int J Obes (Lond) Date: 2007-06-26 Impact factor: 5.095
Authors: Christine M Jewell; Kevin S Katen; Lisa M Barber; Crystal Cannon; Stavros Garantziotis; John A Cidlowski Journal: Am J Physiol Endocrinol Metab Date: 2016-09-06 Impact factor: 4.310
Authors: Draženka Janković; Peter Wolf; Christian-Heinz Anderwald; Yvonne Winhofer; Miriam Promintzer-Schifferl; Astrid Hofer; Felix Langer; Gerhard Prager; Bernhard Ludvik; Alois Gessl; Anton Luger; Michael Krebs Journal: Obes Surg Date: 2012-01 Impact factor: 4.129
Authors: P Mauriège; D R Joanisse; S CasparBauguil; A Cartier; I Lemieux; J Bergeron; S Biron; P Marceau; D Richard Journal: J Physiol Biochem Date: 2015-10-10 Impact factor: 4.158